As FGFR4 is suitable for targeting, these results raise tempting questions, whether FGFR4 inhibition in HER2+ breast cancer would release the intrinsic MST1/2-mediated apoptotic machinery. This evidence concerns the gene ERBB2 and breast carcinoma.